(5-{2-[4-(5-Bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid | 1042428-13-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (5-{2-[4-(5-Bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid
• 英文别名: 2-[5-[2-[4-(5-bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl]tetrazol-2-yl]acetic acid
• CAS: 1042428-13-6
• 化学式: C₁₈H₁₇BrClN₇O₃
• 分子量: 494.735
• InChiKey: JDIQNWGWLRBDBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  119
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  ethyl (5-{2-[4-(5-bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetate 在 甲醇 、 sodium hydroxide 、 水 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 (5-{2-[4-(5-Bromo-2-chlorophenoxy)piperidin-1-yl]pyrimidin-5-yl}-2H-tetrazol-2-yl)acetic acid
  参考文献：
  名称：

  Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase

  摘要：

  结构式I的氮杂环烷衍生物相对于其他已知的硬脂酰辅酶A去饱和酶(SCD1)具有选择性抑制作用。本发明的化合物对于预防和治疗与异常脂质合成和代谢相关的疾病非常有用，包括心血管疾病，如动脉粥样硬化；肥胖；糖尿病；神经系统疾病；代谢综合征；胰岛素抵抗；以及肝脂肪变性。

  公开号：

  US20080182838A1

文献信息

• [EN] COMPOUNDS AS DGAT-1 INHIBITORS<br/>[FR] COMPOSÉS EN TANT QU'INHIBITEURS DE DGAT-1
  申请人：MERCK SHARP & DOHME

  公开号：WO2013096093A1

  公开（公告）日：2013-06-27

  Described herein are compounds of formula I. The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本发明描述了公式I的化合物。公式I的化合物作为DGAT1抑制剂，可用于预防、治疗或作为治疗高脂血症、糖尿病和肥胖的药物。
• [EN] SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] COMPOSÉS CYCLOPROPYLE SUBSTITUÉS, COMPOSITIONS CONTENANT DE TELS COMPOSÉS ET PROCÉDÉS DE TRAITEMENT
  申请人：MERCK SHARP & DOHME

  公开号：WO2011019538A1

  公开（公告）日：2011-02-17

  Substituted cyclopropyl compounds of the formula I: are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.

  取代的环丙基化合物公式I：被披露为用于治疗或预防2型糖尿病和类似病症的有用物质。药物可接受的盐也包括在内。这些化合物作为G蛋白偶联受体GPR-119的激动剂是有用的。
• [EN] DIARYLMETHYLAMIDE DERIVATIVE HAVING MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISM<br/>[FR] DÉRIVÉ DE DIARYLMÉTHYLAMIDE PRÉSENTANT UNE ACTIVITÉ D'ANTAGONISTE DES RÉCEPTEURS DE L'HORMONE DE MÉLANO-CONCENTRATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2011037771A1

  公开（公告）日：2011-03-31

  The present invention is directed to diarylmethylamide derivatives represented of structural formula I which are melanin-concentrating hormone receptor antagonists, and are useful as an agent for the prevention, treatment, or remedy of various circulatory diseases, neurological diseases, metabolic diseases, reproductive system diseases, respiratory diseases, digestive diseases, and the like. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the melanin-concentrating hormone is involved. I

  本发明涉及结构式I所代表的二芳基甲酰胺衍生物，其为黑色素浓集激素受体拮抗剂，并且可用作预防、治疗或缓解各种循环系统疾病、神经系统疾病、代谢性疾病、生殖系统疾病、呼吸系统疾病、消化系统疾病等的药物。该发明还涉及包含这些化合物的药物组合物以及在黑色素浓集激素参与的这些疾病的预防或治疗中使用这些化合物和组合物。
• [EN] SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES<br/>[FR] AMINOPIPÉRIDINES SUBSTITUÉES UTILISÉES EN TANT QU'INHIBITEURS DE LA DIPEPTIDYL PEPTIDASE-IV DANS LE CADRE DU TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011037793A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel substituted aminopiperidines of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-ΪV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

  本发明涉及结构式I的新型取代氨基哌啶，它们是二肽基肽酶-IV酶的抑制剂，并且在治疗或预防二肽基肽酶-IV酶参与的疾病中有用，如糖尿病，特别是2型糖尿病。该发明还涉及包含这些化合物的药物组合物以及在预防或治疗二肽基肽酶-IV酶参与的这类疾病中使用这些化合物和组合物。
• [EN] SPIROXAZOLIDINONE COMPOUNDS<br/>[FR] COMPOSÉS SPIROXAZOLIDINONE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012024183A1

  公开（公告）日：2012-02-23

  Substituted spirocyclic amines of structural formula (I) are selective antagonists of the somatostatin subtype receptor 5 (SSTR5) and are useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as Type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, Metabolic Syndrome, depression, and anxiety.

  结构式（I）的螺环胺是生长抑素亚型受体5（SSTR5）的选择性拮抗剂，可用于治疗、控制或预防对SSTR5拮抗敏感的疾病，如2型糖尿病、胰岛素抵抗、脂质紊乱、肥胖、动脉粥样硬化、代谢综合征、抑郁症和焦虑症。